<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02198391</url>
  </required_header>
  <id_info>
    <org_study_id>920158</org_study_id>
    <nct_id>NCT02198391</nct_id>
  </id_info>
  <brief_title>Study of Echinaforce Junior Tablets in Children With Acute Colds</brief_title>
  <official_title>Multicenter Open-label, Randomized Clinical Trial to Assess the Safety and Efficacy of Echinaforce® Junior Tablets in Two Dosages for the Therapy of Common Cold Symptoms in Children (4-12 Years)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A. Vogel AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>A. Vogel AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate safety and efficacy of Echinaforce Junior tablets in two&#xD;
      dosages of 3 x 1 and 5 x 1 tablets per day in children 4 - 12 years old with acute colds.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2014</start_date>
  <completion_date type="Actual">August 7, 2015</completion_date>
  <primary_completion_date type="Actual">August 7, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>tolerability assessment by physicians</measure>
    <time_frame>4 months</time_frame>
    <description>Within the observation period of 4 months a maximum of 3 colds can be treated with Echinaforce Junior tablets at the indicated dosage. At the exclusion visit the physicians rate the tolerability of Echinaforce Junior tablets as &quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; or &quot;bad&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tolerability assessment by parents/child</measure>
    <time_frame>4 months</time_frame>
    <description>The tolerability of Echinaforce Junior is assessed after every acute treatment period of 10 days and after the observation period of 4 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerability assessment by parents/child</measure>
    <time_frame>10 days</time_frame>
    <description>The tolerability of Echinaforce Junior is assessed after every acute treatment period of 10 days and after the observation period of 4 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of efficacy by parents/child</measure>
    <time_frame>4 months</time_frame>
    <description>The acute efficacy of Echinaforce Junior is rated by the parents after every acute treatment period of 10 days as well as after the observation period of 4 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Cold Symptoms during Acute Treatment</measure>
    <time_frame>10 days</time_frame>
    <description>During acute colds parents complete a symptom diary and assess cold-related symptoms (runny and congested nose, sneezing, headache, joint pain, sore-throat, fever, cough, shivering, sleep quality, additional care) in the child</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">79</enrollment>
  <condition>Respiratory Tract Diseases</condition>
  <arm_group>
    <arm_group_label>3 x 1 tablet per day</arm_group_label>
    <description>Echinaforce Junior tablets (low dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 x 1 tablet per day</arm_group_label>
    <description>Echinaforce Junior tablets (high dose)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        children aged 4 - 12 years recruited in pediatrics practice&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 4 and 12 years&#xD;
&#xD;
          -  signed informed consent by parents and optionally be the child&#xD;
&#xD;
          -  daily access to computer / internet&#xD;
&#xD;
          -  competence of german language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  13 years or older, younger than 4 years.&#xD;
&#xD;
          -  presence of sinusitis, otitis media, pneumonia, bronchitis (complicated cold) at&#xD;
             inclusion&#xD;
&#xD;
          -  participation in a clinical study in the past 30 days&#xD;
&#xD;
          -  intake of antimicrobial, antiviral, immunesuppressive substances, salicyl-containing&#xD;
             medicines or bronchovaxom at first treatment period&#xD;
&#xD;
          -  surgical intervention in the 3 months before inclusion or planned intervention during&#xD;
             the observation period&#xD;
&#xD;
          -  Known diabetes mellitus&#xD;
&#xD;
          -  Known and treated allergic rhinitis, atopy or asthma&#xD;
&#xD;
          -  cystic fibrosis, bronchopulmonic dysplasia, COPD&#xD;
&#xD;
          -  immune system disorders, degenerative diseases (e.g. autoimmune disease like AIDS or&#xD;
             leukosis)&#xD;
&#xD;
          -  metabolic or resorptive disorders&#xD;
&#xD;
          -  liver or kidney diseases&#xD;
&#xD;
          -  serious health problems&#xD;
&#xD;
          -  predisposition for complicated cold episodes in the judgement of the physician&#xD;
             (sinusitis, otitis media, bronchitis, pneumonia)&#xD;
&#xD;
          -  known allergy to plants of the compositae family (camomile or dandelion) or any of the&#xD;
             substances of the investigational product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnold Baechler, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Facharzt FMH für Kinder- u. Jugendmedizin, Notkerstrasse 14 9006 St. Gallen, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. med. Arnold Bächler Facharzt FMH für Kinder- und Jugendmedizin</name>
      <address>
        <city>St. Gallen</city>
        <state>Saint Gallen</state>
        <zip>9000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 22, 2014</study_first_submitted>
  <study_first_submitted_qc>July 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2014</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

